The FDA has approved the Alzheimer’s drug Leqembi from Eisai, Biogen
The U.S. Food and Drug Administration has approved Leqembi’s treatment for Eisai and Biogen’s Alzheimer’s. Medicare announced it would broadly cover Leqembi for patients enrolled in the program for older Americans, though several conditions apply. Medicare coverage is a critical step in helping seniors with early-onset Alzheimer’s disease pay for treatment, which has a list … Read more